RxDoctor Payments Data

Nicole Cohen, MD

Internal Medicine · Savannah, GANPI 1689993081

Payments from drug & device makers

$13,433in general payments, 2019–2025

Across 881 payments — averaging $15.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$2K
  • Pfizer$1K
  • Amgen$926
  • Lilly USA, LLC$826
  • AstraZeneca$805
  • plus $5K from 52 others

What the payments were for

  • Food & beverage$13,433100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk189$2,437
AbbVie(2 entities)113$1,651
Pfizer92$1,370
Amgen(2 entities)68$926
Lilly USA, LLC57$826
AstraZeneca58$805
Astellas Pharma US Inc27$453
Novartis22$403
Boehringer Ingelheim19$374
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC22$349
Sanofi-aventis U.S. LLC16$287
Boston Scientific11$215
Dexcom, Inc.11$202
Esperion Therapeutics, Inc.12$201
Johnson & Johnson11$185
Eisai Inc.9$182
Amarin Pharma, Inc.11$182
Merck11$160
Kowa Pharmaceuticals America, Inc.11$155
Antares Pharma, Inc.8$155
Biohaven Pharmaceutical Holding Company Ltd.6$149
Bayer9$146
GSK9$134
Mannkind Corporation1$121
Otsuka America Pharmaceutical, Inc.6$118
Biohaven Pharmaceuticals, Inc.5$102
Teva Pharmaceuticals USA, Inc.7$95
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$89
Takeda Pharmaceuticals U.S.A., Inc.6$89
E.r. Squibb & Sons, L.L.C.5$83
Genentech USA, Inc.4$64
Endo Pharmaceuticals Inc.4$59
Abbott3$56
Axsome Therapeutics, Inc.3$55
Radius Health, Inc.2$46
Nestle Healthcare Nutrition Inc.2$45
Idorsia Pharmaceuticals US Inc2$42
Ironwood Pharmaceuticals, Inc2$39
ARS Pharmaceuticals Operations, Inc.1$28
Phathom Pharmaceuticals, Inc.2$27
IBSA Pharma Inc.2$27
Aytu Biopharma, Inc.2$27
Xeris Pharmaceuticals, Inc.1$24
Sumitomo Pharma America, Inc.1$21
Alnylam Pharmaceuticals Inc.1$20
Lundbeck LLC1$19
Daiichi Sankyo Inc.1$19
Biogen1$19
Exact Sciences1$18
Shield Therapeutics Inc1$18
Amneal Pharmaceuticals LLC1$17
Redhill Biopharma Inc.1$16
Almatica Pharma LLC1$15
Scilex Pharmaceuticals Inc.1$15
Lifescan, Inc.1$14
Metuchen Pharmaceuticals1$14
Ultragenyx Pharmaceutical Inc.1$14
Hikma Pharmaceuticals USA1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,433 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$220,576
Medicare patients
636
Services billed
2,920

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide173$254,245
MounjaroTirzepatide86$116,766
EliquisApixaban91$102,986
FarxigaDapagliflozin Propanediol25$35,909
XareltoRivaroxaban22$25,179
JardianceEmpagliflozin20$22,193
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$20,849
EntrestoSacubitril/Valsartan12$20,409
LinzessLinaclotide12$18,971
JanuviaSitagliptin Phosphate16$16,890
MyrbetriqMirabegron11$13,190
SynthroidLevothyroxine Sodium112$9,961
Rosuvastatin Calcium546$7,610
Levothyroxine Sodium681$7,233
Atorvastatin Calcium750$6,763

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,437$254,245173 claims
Lilly USA, LLCMounjaro$826$116,76686 claims
PfizerEliquis, Premarin$1,370$105,714103 claims
AstraZenecaFarxiga$805$35,90925 claims
AbbVieLinzess, Synthroid$1,651$28,931124 claims
Johnson & JohnsonXarelto$185$25,17922 claims
Boehringer IngelheimJardiance$374$22,19320 claims
GSKTrelegy Ellipta$134$20,84916 claims
NovartisEntresto$403$20,40912 claims
MerckJanuvia$160$16,89016 claims
Astellas Pharma US IncMyrbetriq$453$13,19011 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$17$7,233681 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →